Healthcare Technology Research Company, KLAS Research, Reports 100% of Surveyed Customers Would Buy Vectramind Health's Firstpass Platform Again
Dubai, United Arab Emirates--(Newsfile Corp. - March 17, 2026) - Vectramind Health today announced that its AI-native patient experience and engagement platform, Firstpass, has received strong validation in a newly released KLAS First Look report highlighting high levels of customer satisfaction and measurable improvements in patient engagement and operational efficiency. The findings, published in the KLAS Research report 'Vect
Technology, Healthcare and Hospitals, Pharmaceuticals
2026-03-17 10:06 AM EDT | Vectramind Health
BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the re
Biotechnology, Pharmaceuticals, Health
2026-03-17 8:30 AM EDT | BioHarvest Sciences Inc.
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company, dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce the discovery of an additional Mechanism Of Action ("MOA") as to how Ruvidar® is
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-03-17 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
King of Prussia, Pennsylvania--(Newsfile Corp. - March 16, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silenc
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-16 11:30 AM EDT | Phio Pharmaceuticals Corp.
Telescope Innovations and AGI SDA Launch Technology Development Collaboration
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") is a developer of enabling technologies and services for the global pharmaceutical and high value chemical industries, with established leadership in sampling systems for monitoring chemical and biological processes. The Company is pleased to announce that it has signed a Development and Collaboration Agreemen
Technology, Chemical, Pharmaceuticals
2026-03-16 8:00 AM EDT | Telescope Innovations Corp.
Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced that it has commenced an underwritten public offering in the United States (the "Offering") of its common shares, no par value (the "Shares"), pursuant to a registration statement filed wi
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-03-16 7:00 AM EDT | Optimi Health Corp.
BioHarvest Sciences Announces Grant of Long-Term Incentive Awards to Employees, Officers and Directors
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that its Board of Directors has approved the grant of long-term incentive ("LTI") awards to employees, officers and directors under the Company's equity incentive plan. These
Biotechnology, Pharmaceuticals, Health
2026-03-13 4:53 PM EDT | BioHarvest Sciences Inc.
Telescope Strengthens Investor Communications Strategy
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) (the "Company"), a leading developer of advanced technologies and services for the global pharmaceutical and high-value chemical industries,has rescoped its previously announced digital marketing agreement dated September 19, 2025, with Gold Standard Media, LLC ("GSM") and its affiliates. In connection with the reduction in scope GSM has refunded the Compan
Technology, Chemical, Pharmaceuticals
2026-03-12 8:30 AM EDT | Telescope Innovations Corp.
BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"), a company that it is a significant shareholder of, has appointed Raj S. Pruthi, MD, MHA, FACS, as a Director of the Company.
Biotechnology, Pharmaceuticals, Health
2026-03-12 3:00 AM EDT | PreveCeutical Medical Inc.
Bachem Reports Strong Sales Growth and Sustained High Profitability
Bubendorf, Switzerland--(Newsfile Corp. - March 12, 2026) - Ad hoc announcement pursuant to Art. 53 LR Bachem Reports Strong Sales Growth and Sustained High Profitability Group sales increase to CHF 695.1 million in 2025 (+14.8%, in local currencies +19.2%). EBITDA increases to CHF 214.7 million (+21.8%, in local currencies +32.6%). EBITDA margin lies at 30.9%. Adjusted for one-time effects of CHF 16.1 milli
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-03-12 1:59 AM EDT | Bachem Holding AG
TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap
Vancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the publication of a clinical case report evaluating the use of VIVI Cap™ for passive thermal protection of insulin during summer travel. The paper, titled "Passive Thermal Protection
Technology, Biotechnology, Pharmaceuticals, Health
2026-03-11 7:00 AM EDT | TempraMed Technologies Ltd.
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-03-10 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
King of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-10 7:00 AM EDT | Phio Pharmaceuticals Corp.
Hemostemix Leadership Attending Abundance360 Summit
Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026 Abundance360 Summit in Los Angeles this week. Founded by futurist and entrepreneur Peter H. Diamandis, the annual Abundance360 Summit convenes leading entrepreneurs, and investors, working at the frontiers of biotechnology, artificial intelligence, longevity science, and other exponential techn
Biotechnology, Pharmaceuticals, Health
2026-03-09 11:23 AM EDT | Hemostemix Inc.
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small
Biotechnology, Pharmaceuticals
2026-03-09 7:30 AM EDT | InMed Pharmaceuticals
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to present its latest preclinical data demonstrating that X-Ray-activated Rutherrin® is effective in th
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-03-09 7:00 AM EDT | Theralase Technologies Inc.
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Montreal, Quebec--(Newsfile Corp. - March 9, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the "Private Placement") of 17,445,455 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of $9,595,000.25. Each Unit is comprised
Biotechnology, Pharmaceuticals, Health
2026-03-09 3:15 AM EDT | Defence Therapeutics Inc.
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned subsidiary of the Company, in light of ongoing uncertainty surrounding U.S. federal legislation. As previously annou
Biotechnology, Pharmaceuticals
2026-03-06 5:04 PM EST | InMed Pharmaceuticals
Shuttle Pharmaceuticals Announces $3.5 Million Public Offering
Gaithersburg, Maryland--(Newsfile Corp. - March 6, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development, today announced that it has entered into a securities purchase agreement with investors for the issuance and sale of 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares of common
2026-03-06 8:00 AM EST | Shuttle Pharmaceuticals Holdings Inc.
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeuti
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-05 4:05 PM EST | Phio Pharmaceuticals Corp.